OncoMatch/Clinical Trials/NCT06251076
Plan Development for Giving Teclistamab in the Outpatient Setting
Is NCT06251076 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments including Teclistamab and Tocilizumab for multiple myeloma.
Treatment: Teclistamab · Tocilizumab — This is a pilot study to develop an outpatient-based process for the administration of teclistamab for for relapsed/refractory multiple myeloma patients and to evaluate the burden on caregivers of patients receiving outpatient administration of teclistamab.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Tumor Agnostic
Performance status
ROCKWOOD CLINICAL FRAILTY SCALE 0–5
Prior therapy
Must have received: proteasome inhibitor
Received at least 3 prior lines of therapy, including a proteasome inhibitor
Must have received: immunomodulatory agent
Received at least 3 prior lines of therapy, including ... an immunomodulatory agent
Must have received: anti-CD38 monoclonal antibody
Received at least 3 prior lines of therapy, including ... an anti-CD38 monoclonal antibody
Cannot have received: anti-BCMA therapy (teclistamab)
Prior or concurrent exposure to any of the following: Teclistamab or any anti-BCMA therapy
Cannot have received: other myeloma therapy (standard of care or investigational) including corticosteroids
Exception: within 3 days of first step-up dose of teclistamab
Other myeloma therapy (standard of care or investigational) including corticosteroids, within 3 days of first step-up dose of teclistamab
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify